Search

Your search keyword '"Jain, Michael"' showing total 720 results

Search Constraints

Start Over You searched for: Author "Jain, Michael" Remove constraint Author: "Jain, Michael"
720 results on '"Jain, Michael"'

Search Results

1. Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma

2. Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium.

5. The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma

6. Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-Cell therapy: an exploratory study

7. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy

8. Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium

9. Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma

13. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.

14. Bringing CAR-T to the Clinic

15. Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma

16. Autologous Hematopoietic Cell Transplantation Consolidation for First Response is Associated With Longer Survival Among Patients With Nodal Peripheral T Cell Lymphoma

17. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma

18. A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma

20. Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium

22. A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease

23. Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy

25. Mismatched donor allogeneic hematopoietic cell transplantation with post‐transplant cyclophosphamide achieves comparable outcomes between racially and ethnically diverse patient populations

26. Abstract P23: RHOA inactivation subverts IFN-γ response and promotes antigen escape in CAR-T resistant diffuse large B-cell lymphoma

27. Table S5 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma

28. Data from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma

29. Figure S2 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma

30. Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma

31. Identification of Pre-Treatment Clinical Risk Factors Predictive of Inferior Survival and Increased Risk of Treatment Failure in CD19 Chimeric Antigen Receptor T Cell Recipients with Large B Cell Lymphoma.

32. Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US)

33. Outcomes of Haploidentical Stem Cell Transplant Recipients with HHV-6 Reactivation Receiving Antiviral Therapy

34. Expanded Antigen-Specific Donor Regulatory T Cells for Gvhd Prevention

35. Evaluation of Outpatient Administration of Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma: Single Center Experience

36. Increased Infections and Delayed CD4+ T Cell but Faster B Cell Immune Reconstitution after Post-Transplantation Cyclophosphamide Compared to Conventional GVHD Prophylaxis in Allogeneic Transplantation

37. Abstract 10475: Serial Inflammatory Cytokine Levels Are Increased in Atrial Fibrillation After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

38. A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation

39. Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome

41. Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma

43. Branched-chain keto acids promote an immune-suppressive and neurodegenerative microenvironment in leptomeningeal disease

44. Outcomes among adult recipients of CD19 CAR T-cell therapy for Burkitt lymphoma

45. Supplementary Figure S8 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11

46. Data from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11

47. Supplementary Methods S1 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11

48. Supplementary Table S2 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11

Catalog

Books, media, physical & digital resources